key: cord-0818103-dvzv2yvd
authors: Zhang, X.; Sumathipala, M.; Zitnik, M.
title: Population-scale patient safety data reveal inequalities in adverse events before and during COVID-19 pandemic
date: 2021-01-20
journal: nan
DOI: 10.1101/2021.01.17.21249988
sha: 6d66865df2c8231fffa8218cdabde18daf3e2c26
doc_id: 818103
cord_uid: dvzv2yvd

Adverse patient safety events were associated with 110 thousand deaths in the U.S. alone in 2019. The COVID-19 pandemic has further challenged the ability of healthcare systems to ensure medication safety, and its effects on patient safety remain unknown. Here, we investigate negative outcomes associated with medication use before and during the pandemic. Using a dataset of 10,443,476 reports involving 3,624 drugs and 19,193 adverse events, we develop an algorithmic approach to analyze the pandemic's impact on incidence of drug safety events by evaluating disproportional reporting relative to the pre-pandemic time, quantifying unexpected trends in clinical outcomes, and adjusting for drug interference. Among 64 adverse events identified by our analyses, we find 54 have increased incidence rates during the pandemic, even though reporting of adverse events has decreased by 4.4% overall. We find clinically relevant differences in drug safety outcomes between demographic groups. Comparing to male patients, women report 47.0% more distinct adverse events whose occurrence significantly increased during the pandemic relative to pre-pandemic levels. Out of 53 adverse events with the pre-pandemic gender gap, 33 have increased gap during the pandemic more than would have been expected had the pandemic not occurred. While musculoskeletal and metabolic side effects are disproportionately enriched in women during the pandemic, immune-related adverse events are enriched only in men. We also find the number of adverse events with a higher reporting ratio during the pandemic in adults is higher (16.8%) than in older patients (adjusted for population size). Our findings have implications for safe medication use and public health policy and highlight the role of variation in adverse events for improving patient safety during a public health emergency.

Adverse events from medications [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Further, such narrowly focused analyses can be confounded by historical biases in adverse event 35 reporting and by mixing population groups that differ in their relative risks for clinical events. 36 We systematically investigate the impact of COVID-19 on the incidence of adverse drug 37 reactions using a population-scale patient safety dataset. We analyze 10,443,476 adverse event re-38 ports spanning 19,193 adverse events and 3,624 drugs to reveal previously unknown impacts of the 39 pandemic on drug safety and identify variation in adverse events across diverse patient populations. 40 Disentangling confounders (such as sampling variance and temporal biases in reporting of adverse 41 events), our algorithm identifies sex-and age-related variations in adverse events and demographic 42 groups who are at higher or lower risk for adverse events during the pandemic than in the pre-43 pandemic time. The analyses enable insights into the inter-correlated adverse events, distill drug 44 safety signals, and yield hypotheses based on risk-altering interactions to inform drug prescription. 45 We also present a comprehensive catalog of adverse events that can serve as a valuable resource 46 to discover relationships between drugs and safety events, especially in cases of rare events and 47 rectly related to COVID-19, such as coronavirus infection, coronavirus test positive, COVID-19, 85 suspected COVID-19, and COVID-19 pneumonia (all p-value < 10 −37 , Fisher's exact test): we 86 exclude these from the rest of our analyses. The model detected 64 unique adverse events whose 87 incidence changed during the pandemic in the overall population: 54 of which have increased re-88 porting frequency during the pandemic, while only 10 decreased in frequency (SI Figure S1 ). We 89 define adverse drug reactions whose reporting frequency has disproportionately increased with the 90 pandemic onset as enriched, and those with significantly decreased reporting frequency as purified. 91 Among the 54 enriched adverse events, delusion has the greatest association with the pandemic, 92 with the largest PAEAI score of 1.95 (statistics for more adverse events in SI Table S1 ). The vol-93 ume of FAERS reports involving drug-related premature delivery increased 73.4%, despite studies 94 from the US and Europe finding a decrease in the overall incidence of preterm births during the 95 pandemic [33] [34] [35] . Similarly, the incidence of drug-related bladder cancers increased by 147%, 96 despite overall decrease in cancer diagnoses after the onset of the pandemic [15] . The frequency of 97 hallucination side effects increased 138% during the pandemic compared to before the pandemic, 98 which could be related to reports linking paranoia about COVID-19 to hallucinations, as well as 99 the neurological impacts of the disease itself [36, 37] . Our framework also detects large increases 100 for severe side effects, such as respiratory failure and cardiac arrest. The domination of adverse 101 events with increased frequency is consistently observed in most demographics across sex and age. 102 For instance, in patients over 65 years old, 18 out of 19 identified adverse events are enriched, and 103 only one is purified (SI Figure S1 ). 104 Women suffer from more drug adverse events than men relative to pre-pandemic levels 105 While our approach detected 38 adverse events that increased in frequency in women (SI Table S3 ), 106 only 16 enriched adverse events were detected in men (SI Table S2 ; Figure 2a ). This finding is 107 consistent with that 62.0% of all reports in FAERS are from women and only 38.0% from men 108 (excluding reports with unknown sex). Even after normalizing to the greater number of female brought on by the pandemic exert greater influence on the incidence in female patients. 117 Proportion of female patients increased across most enriched adverse events 118 Next, we assess the proportion of female patients in each of 54 side effects that were enriched in 119 the overall population, comparing the proportion before and during the pandemic (Figure 2d ). We 120 exclude premature delivery, for which all patients are female. We find the proportion of female 121 patients increased in 40 out of 53 adverse events during the pandemic. The two adverse events 122 with the largest increases are reduced visual acuity, where the proportion of women increased from 123 53.8% to 75.2%, and neuroleptic malignant syndrome, where the proportion of women increased 124 from 18.4% to 39.0%. We find the proportion of women in drug-related anxiety reports increased 125 from 67.8% to 72.3%, confirming that women report anxiety at higher rates during the pandemic 126 than men [38] . We observe an increase in the proportion of reports for side effects associated with 127 anxiety disorders: insomnia, dysponoea (shortness of breath), and dizziness, but find a decrease in 128 side effects commonly associated with psychosis disorders: delusion, hallucinations, and dementia.

Our analyses identify 13 adverse events for which the proportion of female patients has de-130 creased while the proportion of male patients increased (SI Figure S7 ). For example, the proportion 131 of hypogammaglobulinaemia reports with female patients dropped steeply from 70.6% to 41.2% 132 during the pandemic. As patients with hypogammaglobulinaemia are immunocompromised and at 133 higher risk for COVID-19, this finding warrants investigation into why the incidence of hypogam-134 maglobulinaemia decreased in women and if there is an increase in undiagnosed cases.

Variation in drug adverse events across age groups Table S4 ), 35 in adults (SI Table S5 ), and 18 in elderly patients (SI Table S6 ). Even 138 after accounting for the differences in the size of each patient cohort, there are still 68.8 side effects 139 per million adults with increased reporting frequency during the pandemic, which is greater than 140 the 27.8 side effects per million young patients and 58.9 adverse events per million elderly. The 141 one side effect enriched in young patients, pyrexia (PAEAI =1.08), is similarly enriched during the 142 pandemic in adults (PAEAI =1.22), but is not significantly impacted in the elderly. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 20, 2021. lower rates of overall anxiety-, depression-, and stress-related disorders in the elderly compared to 154 younger age groups and suggests that drug-induced psychiatric effects may need to be addressed 155 differently by healthcare systems.

Variation in adverse events across organ systems 157 We divide 54 adverse events found to be enriched in the overall population into 19 categories based Ten adverse events have their reporting frequency disproportionately decreased during the 164 pandemic, four of which are urinary system disorders and two are blood-related adverse events 165 (SI Figure S3 ). Although the incidence proportion are decreased in reports submitted by pro-166 fessional healthcare workers, we find five adverse events (infective pulmonary exacerbation of 167 cystic fibrosis, chronic kidney disease, osteonecrosis of jaw, renal injury, and nausea) have more 168 self-reported cases (submitted by customer themselves) during the pandemic in contrast to before 169 pandemic (SI Figure S8 -S9). In particular, reports of kidney injury have dropped dramatically 170 among professionals, but have risen sharply among non-professionals, suggesting an unmet need 171 for pharmacovigilance in drug-related renal injury during the pandemic. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.17.21249988 doi: medRxiv preprint musculoskeletal, skin, infections, and pregnancy-related disorders. Although psychiatric adverse 180 events are enriched in both men and women, there are four psychiatric side effects in men, and only 181 two in women: hallucination is enriched in both; the incidence of anxiety is increased in females 182 but not in males, while alcoholism, delusion, and dementia are only enriched in male patients.

Psychiatric adverse events are overrepresented in the elderly, with five enriched adverse 184 events, compared to only one in adults: lending further support to our finding that the elderly 185 may be differentially susceptible to psychiatric side effects of medications. In particular, halluci-186 nation, delusion, abnormal behaviour, aggression, and dementia are enriched in the elderly but not 187 adults, while anxiety is only enriched in adults. Moreover, in the elderly, we observe one eye-and 188 one ear-related adverse events (vitreous floaters and hypoacusis, respectively), but do not detect ei-189 ther in adults. Across sex and age cohorts as well as in the overall population, vascular-related side 190 effects are enriched, suggesting it is a class of adverse drug reactions whose incidence is widely 191 impacted by the pandemic.

Pre-pandemic gender differences are exaggerated during the pandemic 193 We further investigate gender disparities among the enriched adverse events, and whether any pre- Considering adults and elderly, we observe a similar increase in pre-existing gender dispari-211 7 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.17.21249988 doi: medRxiv preprint that contradict the literature (e.g., increased susceptibility of the elderly to drug-related psychiatric 275 events, despite documented resilience to psychiatric disorders). The models detect novel, rare ad-276 verse events, such as hypoxia as a side effect of Remdesivir, highlighting the role of algorithmic 277 models for pharmacosurveillance of treatments granted emergency approval.

The power to detect subtle patterns of drug safety depends on the algorithm's ability to 279 exclude potential confounding factors. To account for well-recognized confounding factors, we 280 directly compare reports submitted in 2020 to those in 2019 and use temporal prediction between 281 2013 and 2020 to identify drug safety events whose reporting changed during the pandemic more Our algorithmic approach can identify differential reporting patterns in patient cohorts formed 295 as a function of gender, age, adverse events, and drugs. With additional information on medical and 296 non-medical patient characteristics such as race and ethnicity, the approach is suitable for system- is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.17.21249988 doi: medRxiv preprint Data availability. All data used in the paper, including the raw and processed adverse event 304 report dataset, adverse event ontology, drug ontology, the final and intermediate results of the 305 analyses will be shared with research community via https://zitniklab.hms.harvard.edu upon pub-306 lication.

Code availability. Python implementation of methodology used in the study will be available 308 upon publication via https://zitniklab.hms.harvard.edu. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. 12 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. Values listed indicate the number of averse events associated with each patient cohort and are divided into groups by etiology of adverse events (Methods). In the overall population, nervous and vascular SOCs are most common, with nine and seven side effects, respectively. The representation of enriched psychiatric adverse events varies: four out of 16 adverse events in men (25%) and five out of 18 in the elderly (27.8%), compared to only two out of 38 in women (5.3%) and one out of 35 in adults (2.9%). There is one overrepresented and one underrepresented drug side effect in young patients (SI Figure S2-S3). (b) The proportion of female patients in the 53 side effects enriched in the overall population (omitting reports with unknown sex and excluding premature delivery which only occurs in women). In the majority (75.5%) of side effects, female patients account for a higher proportion of reports during the pandemic, compared to before the pandemic. (c) Changes to gender disparities in the 53 side effects enriched in the overall population during the pandemic (same 53 as in panel b). The gap in the number of reports for men and women is exacerbated during the pandemic in most (41/53) of the adverse drug events. We annotate the top five adverse events that have the largest increase (bolded), with the first number indicating the absolute difference in number of reports, and the number in parentheses showing the difference normalized by population size. For example, a normalized gap of 4.08 in dysponea indicates there are 4.08 more reports per thousand women than per thousand men (negative numbers indicate the reporting frequency in women is smaller than in men, even though the absolute number of reports may be higher in women). Considering incidence proportion (the number of reports per thousand patients) of adverse events (SI Figure S4 ): we find that the gender disparity is enlarged in 33 out of 53 the adverse drug reactions during the pandemic, consistent with the trend observed in the absolute number of reports.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. Figure 3 : Disparities across gender and age. (a) PAEAI values differ in men and women. Higher PAEAI indicates the incidence of a drug-related side effect has undergone a greater change during pandemic than pre-pandemic and that change cannot be explained by temporal trends. We find 10 adverse drug reactions show significant association with the pandemic only in men but not in women, whereas 31 are associated with the pandemic only in women. (b) Age differences in PAEAI. We find that adults have more drug adverse events whose reporting frequency was impacted by the pandemic, compared to the young and elderly cohorts. Pyrexia is significantly associated with the pandemic in both young and adult cohorts. There are no side effects impacted by the pandemic in both young and elderly individuals. The algorithmic approach detects six adverse drug reactions impacted in both adults and the elderly. The majority (28/35, 80.0%) of adverse events observed in adult patients are not found in other age groups. In contrast, there are 12 out of 18 drug reactions in elders are not found in adults. (c) Gender gap in adults (omitting reports with unknown sex). We detected 35 enriched adverse events in adults, and omitted premature delivery and 10 that were only observed in reports with unknown sex: leaving 24 with gender difference. Pre-pandemic gender disparities are increased in 21 out of 24 (87.5%) adverse events, in response to the pandemic. Of these 21 adverse events, 18 have more reports involving women than men, suggesting a disproportionate vulnerability in adult women for gender disparities. Regarding incidence proportion, we note that the gender gap is magnified in 70.8% of the adverse events (SI Figure S5 ). (d) Gender gap in the elderly (omitting reports with unknown sex). In 13 out of 14 adverse drug events (18 adverse events significantly associated with the pandemic in elderly patients, 4 only observed in unknown sex and omitted), a pre-existing gender gap is intensified during the pandemic. Five among these drug side effects (5/13, 38.5%) are reported in more males than females during the pandemic, while only 3 out of 24 side effects (3/24, 12.5%) in adults: indicating the gender inequality is mitigated in aged people in contrast to adults. With the onset of pandemic, gender discrepancy (in terms of incidence proportion) has worsened in 11 out of 14 adverse events where gender inequality previously existed (SI Figure S6 ; adjusted for population size).

14 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. (a) Drug-adverse event associations enriched in women during the pandemic more than would have been expected had the pandemic not occurred. (b) Drug-adverse event associations enriched in men during the pandemic more than would have been expected had the pandemic not occurred. The network in women has more edges (169 associations) than in men (51 associations), suggesting there are significant levels of drug safety inequities that disproportionately impacted women during the pandemic, compared to men. Associations between cardiac arrest and nervous system drugs are found in both networks. A link between Remdesivir and respiratory failure is found in male but not in female patients.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.17.21249988 doi: medRxiv preprint

The Methods is structured as follows: 1) description of datasets used, 2) description of the algo-319 rithmic approach for constructing population-specific models of patient safety. hierarchy. We allow selective exclusion before feeding data into the proposed framework. We 374 manually remove the adverse events related to four SOCs (i.e., social circumstances, surgical and 375 medical procedures, product issues, and investigations) that are not related to medication therapies. 376 Furthermore, to increase the robustness and generalizability of the results, we focus on the adverse 377 events that are observed in at least 100 reports either before or during the pandemic.

17 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.17.21249988 doi: medRxiv preprint Mapping of drugs, controlled drug vocabulary, and Anatomical Therapeutic Chemical 379 (ATC) classification system. We first map the drugs in the AE reports to DrugBank IDs (https: 380 //go.drugbank.com) [68] . We implement the same mapping strategy as described in the section on 381 mapping of adverse events. We also group drugs into categories given by the Anatomical Ther- Overview of the approach. The approach receives multimodal information including drugs, ad-390 verse events, and demographic (e.g., gender and age) from adverse event reports in order to identify 391 the substantial drug side effects that are significantly associated with pandemic, and detect the in- Next, we take the overall population (SI Table S1 ) as an example to introduce the pipeline of 401 proposed framework. Our model can be flexibly generalized to any demographic subpopulations 402 (such as SI Table S2 -S6) by adjusting the input reports. We start with the notation and mathematical 403 representation of the dataset, and then describe details of the three components.

Notation and representation of adverse event data. We denote the FAERS dataset as X where 405 each element x i represents a single patient safety report. We use D and S to denote the set of 406 all drugs and adverse events appeared in FAERS dataset, respectively. We regard each report as 407 a tuple including a set of drugs D i , a set of adverse events S i , patient's age a i , sex g i , weight 408 18 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.17.21249988 doi: medRxiv preprint w i , reporter's qualification q i , severity vector b i , and reporting date t i ; in other words, we have

The patient may take several medications at the same time and 410 have multiple adverse drug events. Thus, each report contains a drug set D i , which is a subset of D, 411 and each drug d j ∈ D i is represented by its DrugBank ID (string). Similarly, the adverse events set 412 S i ⊆ S contains one or more drug side effects and each s h ∈ S i is represented by its MedDRA ID 413 (string). The patient's age (in year) a i is represented by an integer; the biological sex is denoted by k, which are connected with logical connectives: negation ("not" or ¬), logical conjunction ("and" 433 or ∧), logical disjunction ("or" or ∨), existential quantification (∃), and universal quantification (∀). 434 We use "·" to denote free/unbound variables. As an example, a logical predicate L = (¬d j , s h , ·) 435 denotes the following conjunctive connection: "Report describes a patient who does not take drug . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. ; satisfy logical predicate L. We formulate the value of f as:

where N represents the number of AE reports that satisfy the atomic formulas of drug d j , adverse Table S7 ); γ(d j , s h ) quantifies the connection between drug d j and adverse 451 event s h (SI Table S8 ); δ(d j , s h ) estimates the association between drug-adverse event pair (d j , s h ) 452 and the pandemic (SI Table S9 ).

Step 1) Disproportionality estimation. We conduct the disproportionality estimation is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. underrepresented (β(s h ) < 1) adverse events.

Step 2) AE reporting trajectories. The reporting trajectory of an adverse event refers to the 478 changing trend of adverse event incidence proportion, indicated by its temporal/historical data.

For example, if the reporting frequency of a certain adverse drug reaction has continually increased 480 from 2013 to 2019, it is not surprise that it also grows from 2019 to 2020, and we cannot assertively 481 attribute its overrepresentation to the pandemic. Addressing this issue, we propose a dedicated 482 indicator, pandemic-adverse event association index (PAEAI), to measure whether a medication's 483 incidence conforms to its trajectory. We next report how to reduce the confounding factor of 484 temporal trend in single adverse event level. indicates more substantial changes in the reporting frequency of s h . As PAEAI takes the logarithm, 508 a small difference in PAEAI reflects a rather large change during the pandemic relative to pre-509 pandemic levels. In the next step of the approach we only consider s h with positive PAEAI.

Step 3) Drug interference. Next, we reduce the confounding effects of multiple drugs. Tra-511 ditional pharmacosurveillance typically only concern how adverse events connected to specific 512 therapy [32], however, our approach able to discover multiple drugs that may explain the change 513 of reporting frequency during the pandemic, and control underlying variables in analysis. We 514 consider two types of medication interference:

• The first interference is that the adverse event co-occur with a certain drug in safety reports but 516 their association may not significant.

• The second interference is that the association between an adverse event and the pandemic can be 518 attributed to multiple drugs, however, none of the formed drug-adverse event pairs is significantly 519 associated with the pandemic.

Accordingly, we consider two aspects to prevent drug interference. First, the adverse event (such 521 as hallucination) should be significantly associated with the therapy of at least one drug (like Pi-522 mavanserin). Second, the formed drug-adverse event pair (like Pimavanserin-hallucination) should 523 be significantly associated with the pandemic.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.17.21249988 doi: medRxiv preprint

To eliminate the first interference, for a certain adverse event s h that has passed the selection 525 in previous two components, we go through all the drugs that co-occurred with it in adverse event 526 reports during the pandemic (i.e., X 2020 ). We use N s h to denote the set of found drugs for s h . 527 We only check association between s h and d j ∈ N s h during the pandemic, for simplification, we 528 omit the subscript of year while analyzing the first medication interference. For a specific drug 529 d j ∈ N s h , we regard the reports where the drug is involved as positive samples (X d j ), while not 530 involved as negative samples (X ¬d j ). All the positive samples are included in a test group T d j . To 531 keep the comparison fair, we select a subset from negative samples as control group C d j where the 532 patients have similarly situation with the ones from T d j (i.e., T d j = X d j and C d j ∈ X ¬d j ) [67, 79].

The reports in C d j are selected through a nearest neighbour propensity score matching model [79] 534 which measures the similarity between a report (a patient) from negative samples with a report from 535 positive samples as a function of the patient characteristics. Based on the available information, 536 we build a characteristic factor z i = [a i , g i , w i , q i , b i,1 , . . . , b i,6 , t i ] for each report, including the 537 patient's age, sex, weight, the qualification of the reporter, severity vector (b i,1 to b i,6 are the six 538 elements in b i ) and the submission date. For each report in test group C d j , we select 10 reports 539 that have the highest propensity scores into control group [67], which makes |C d j | = 10|T d j |. The 540 propensity scores are measured by the cosine similarity among characteristic factor. Afterwards, 541 based on C d j and T d j , we define γ(d j , s h ) for each s h and all it's co-occurred drug d j ∈ N s h by: 

where f (d j , s h , 2020) represents the quantity of reports that exposed to a certain drug d j and mean-543 while emerged the specific drug reaction s h , whereas f (d j , ¬s h , 2020) denotes the number of re-544 ports that also exposed to d j but not emerged s h ; f (¬d j , s h , 2020) represents the number of re-545 ports that not involves d j but generated s h , while f (¬d j , ¬s h , 2020) denotes the amount of reports 546 that not involves d j and not contain s h . We quantify the upper/lower 95% CI of γ(d j , s h ) by 547 e ln(γ(d j ,s h ))±1.96

√ 1/f (d j ,s h ,2020)+1/f (d j ,¬s h ,2020)+1/f (¬d j ,s h ,2020)+1/f (¬d j ,¬s h ,2020) (SI Table S8 ).

The passing requirements are the 95% CI of γ(d j , s h ) not cross one and the p-value corrected 549 by Bonferroni method smaller than 0.05. To this end, for each s h , we have a drug set N s h which is 550 a subset of N s h , where each drug d j ∈ N s h is significantly associated with s h .

To alleviate the impact of the second interference, we further explore whether each drug-552 adverse event pair is significantly related to the pandemic in contrast to before the pandemic. We 553 23 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.17.21249988 doi: medRxiv preprint only consider s h that is significantly associated with at least one drug (i.e., N s h = ∅). We then 554 define δ(d j , s h ), denoting the odds ratio of pair (d j , s h ) (where d j ∈ N s h ) during the pandemic, Table S9 ). The cri- icantly associated with the pandemic. At last, any adverse event s h with N s h = ∅ satisfies that 564 its changed reporting frequency can be attributed to at least one medication, and the drug-adverse 565 event pair is significantly associated with the pandemic.

In summary, each adverse event s h identified by our approach have multiple defined metrics 567 describing different aspects. The β (along with 95% CI and adjusted p-value) detects the report- 24 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.17.21249988 doi: medRxiv preprint

Reporting of adverse events

Adverse outpatient drug events-a problem and an opportunity

Using machine learning to identify adverse drug effects posing 581 increased risk to women

Predicting the frequencies of drug side 583 effects

Adverse drug events in ambulatory care

Reported adverse drug reactions in 587 women and men: aggregated evidence from globally collected individual case reports during 588 half a century

Adverse drug reactions: definitions, diagnosis, and manage-590 ment

Incidence of adverse drug events and potential adverse drug events: impli-592 cations for prevention

Serious adverse drug events reported to the food 594 and drug administration

Severe cutaneous ad-596 verse reactions to drugs

Machine learning guided association of adverse drug reactions with in vitro 598 target-based pharmacology

Drug-associated adverse events in the treatment of multidrug-resistant tubercu-600 losis: an individual patient data meta-analysis

Perception of severity of adverse events in oral immunotherapy

The effect of large-scale anti-contagion policies on the COVID-19 pandemic. 605

Changes in the number of US patients 607 with newly identified cancer before and during the coronavirus disease 2019 (COVID-19) 608 pandemic

Age-specific mortality and immunity patterns of SARS-CoV-2

Mobility network models of COVID-19 explain inequities and inform reopen-612 ing

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound re-614 purposing

A SARS-CoV-2 protein interaction map reveals targets for drug repurpos-616 ing

Virological assessment of hospitalized patients with COVID-2019

Sex differences in immune responses that underlie COVID-19 disease 620 outcomes

Air pollution and COVID-19 622 mortality in the united states: strengths and limitations of an ecological regression analysis

Health risks and outcomes that disproportionately affect women during the 625 COVID-19 pandemic: a review

Emergency hospitalizations 627 for adverse drug events in older americans

Prevalence of prescription medications with de-630 pression as a potential adverse effect among adults in the united states

Predicting adverse drug events using pharmaco-633 logical network models

Multi-omics prediction of immune-related adverse events during checkpoint 635 immunotherapy

Synergistic and low adverse effect cancer immunotherapy by immunogenic 637 chemotherapy and locally expressed pd-l1 trap

Predicting erenumab adverse events with single-cell genomics

Adverse events associated with potential drugs for COVID-19: a 641 case study from real-world data

Effect of remdesivir vs standard care on clinical status at 11 days in 643 patients with moderate COVID-19: a randomized clinical trial

Identifying side effects of commonly used drugs in the 645 treatment of COVID 19

Risk of congenital birth defects during COVID-19 pandemic: draw 647 attention to the physicians and policymakers

Decreased incidence of preterm 649 birth during COVID-19 pandemic

The COVID-19 pandemic 652 and human fertility

Neurologic manifestations of hospitalized patients with coronavirus disease 654 2019 in wuhan, china

Paranoia, hallucinations and compulsive buying during 656 the early phase of the COVID-19 outbreak in the united kingdom: a preliminary experimental 657 study

Anxiety, depression, and related factors in pregnant women 659 during the COVID-19 pandemic in turkey: a web-based cross-sectional study. Perspectives in 660 Psychiatric Care

Mental health, substance use, and suicidal ideation during the COVID-19 662 pandemic-United States

Older adults and the mental health effects of 665 COVID-19

The medical dictionary for regulatory activities (Med-667 DRA)

COVID-19-a vascular disease

A prospective study of neurologic disorders in hospitalized COVID-19 671 patients in new york city

Factors contributing to susceptibility of postmenopausal women to 673 recurrent urinary tract infections

The opioid epidemic within the COVID-675 19 pandemic: Drug testing in 2020

New trends of substance abuse during COVID-19 677 pandemic: an international perspective

Immediate impact of stay-at-home orders to control COVID-19 trans-679 mission on socioeconomic conditions, food insecurity, mental health, and intimate partner 680 violence in bangladeshi women and their families: an interrupted time series

Women's mental health in the time of COVID-19 683 pandemic

The implications of COVID-19 for mental health and substance use

Changes in adult alcohol use and consequences 687 during the COVID-19 pandemic in the US

FDA approval of remdesivir-a step in the 690 right direction

Compassionate use of remdesivir for patients with severe COVID-19

Remdesivir in adults with severe COVID-19: a randomised, double-blind, 694 placebo-controlled, multicentre trial

Safety profile of the antiviral drug remdesivir: an 696 update

Gender differences in medication use: a drug utilization study based on 698 real world data

The impact of visitor restric-701 tions on healthcare-associated respiratory viral infections during the COVID-19 pandemic: 702 experience of a tertiary hospital in singapore

A tale of two pandemics: 705 how will COVID-19 and global trends in physical inactivity and sedentary behavior affect one 706 another?

Data mining differential clinical outcomes associated with drug regimens 708 using adverse event reporting data

Machine learning guided association of adverse drug reactions with in vitro 710 target-based pharmacology

SGLT2 inhibitors and amputations in the US FDA Adverse Event 712

Reporting of immune checkpoint inhibitor-associated my-714 ocarditis

Automatically recognizing medication and adverse event information 716 from food and drug administration's adverse event reporting system narratives

Data mining at FDA-white paper

US food and drug 720 administration reports of pregnancy and pregnancy-related adverse events associated with 721 isotretinoin

ATC/DDD classification

Men, ageing and health: achieving health across the life span

Data-driven prediction of drug 726 effects and interactions

Drugbank 5.0: a major update to the DrugBank database for

Convalescent plasma treatment of severe COVID-19: a propensity score-730 matched control study

Early outcomes of perioperative statin therapy 732 for elderly patients undergoing off-pump coronary artery bypass surgery: a propensity score-733 matched study

Risk of cancer in patients with polycystic kidney disease: a propensity-score 735 matched analysis of a nationwide, population-based cohort study

Disproportionality analysis for phar-738 macovigilance signal detection in small databases or subsets: recommendations for limiting 739 false-positive associations

Male sex identified by global COVID-19 meta-analysis as a risk factor for 741 death and itu admission

SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare 743 workers in sweden

Association of hyponatraemia and antidepressant drugs: a 745 pharmacovigilance-pharmacodynamic assessment through an analysis of the US food and 746 drug administration adverse event reporting system (FAERS) database

Sex-specific outcome disparities in very old patients admitted to intensive 749 care medicine: a propensity matched analysis

Evaluation of the safety 751 profile of rotavirus vaccines: a pharmacovigilance analysis on American and European data

Nearest neighbour propen-755 sity score matching and bootstrapping for estimating binary patient response in oncology